StockData

NextCure, Inc. (NXTC) stock

NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$6.70+0.02 (+0.30%)

Close on Nov 17, 2026Market cap $30.67MP/E –Yield 0.00%

NextCure price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

NextCure's price to sales ratio was 10.8× on Apr 30, 2021, against 140.5× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2021Apr 30, 202110.8×−1.5
2020Dec 31, 202012.3×–

More NextCure figures

See a number that looks wrong?